Shrimp Disease Prevention and Therapeutics Market Size, Share Detailed Report 2026 to 2035
Market Segmentation:
Shrimp Disease Prevention & Therapeutics Market by Product Type -
• Disease Prevention
o Probiotics & Microbial Products
o Vaccines & Immunostimulants
o Functional Health Feeds & Nutraceuticals
o Biosecurity, Disinfectants & Diagnostics
o Disease-Resistant Broodstock & Genetics
• Therapeutics
o Antibiotics
o Antiparasitic & Antifungal Agents
o Antivirals & Supportive Therapeutics
o Chemical Disease-Control Treatments
Shrimp Disease Prevention & Therapeutics Market by Disease Type-
• Viral Diseases
o White Spot Syndrome Virus (WSSV)
o Taura Syndrome Virus (TSV)
o Yellow Head Virus (YHV) / Gill-Associated Virus (GAV)
o Infectious Myonecrosis Virus (IMNV)
o White Muscle / White Tail Viral Diseases
o Others
• Bacterial Diseases
o Vibriosis
o Acute Hepatopancreatic Necrosis Disease (AHPND/EMS)
o Vibrio-associated Hepatopancreatic Infections
• Bacterial Shell Diseases
o Chronic Bacterial Septicemia
o Parasitic & Microsporidian Diseases
o Enterocytozoon Hepatopenaei (EHP)
o Gregarine Parasitic Infections
o Protozoan Fouling Parasites
o Others
• Fungal & Opportunistic Pathogens
Shrimp Disease Prevention & Therapeutics Market by Route of Administration -
• Oral
• Water / Immersion / Bath Application
• Injectable Delivery
• Topical & External Application
• Others
Shrimp Disease Prevention & Therapeutics Market by End-User -
• Grow-Out Farms
• Hatcheries & Nurseries
• Integrated Farming & Feed Companies
• Diagnostic Laboratories & Research Institute
IoT Sensors & Predictive Analytics for Precision Aquaculture Market by Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• India
• Vietnam
• Indonesia
• Thailand
• Bangladesh
• Rest of Asia Pacific
Latin America-
• Brazil
• Mexico
• Ecuador
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Shrimp Disease Prevention & Therapeutics Market Snapshot
Chapter 4. Global Shrimp Disease Prevention & Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035
4.8. Global Shrimp Disease Prevention & Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2025-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2025)
4.10. Use/impact of AI on Non-Chemical Water Disease Type & Pond Ecosystem Management in Aquaculture Industry Trends
Chapter 5. Shrimp Disease Prevention & Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Product Type:
5.2.1. Disease Prevention
5.2.1.1. Probiotics & Microbial Products
5.2.1.2. Vaccines & Immunostimulants
5.2.1.3. Functional Health Feeds & Nutraceuticals
5.2.1.4. Biosecurity, Disinfectants & Diagnostics
5.2.1.5. Disease-Resistant Broodstock & Genetics
5.2.2. Therapeutics
5.2.2.1. Antibiotics
5.2.2.2. Antiparasitic & Antifungal Agents
5.2.2.3. Antivirals & Supportive Therapeutics
5.2.2.4. Chemical Disease-Control Disease Types
Chapter 6. Non-Chemical Water Disease Type & Pond Ecosystem Management in Aquacultur Market Segmentation 2: By Disease Type, Estimates & Trend Analysis
6.1. Market Share by Disease Type, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Disease Type:
6.2.1. Viral Diseases
6.2.1.1. White Spot Syndrome Virus (WSSV)
6.2.1.2. Taura Syndrome Virus (TSV)
6.2.1.3. Yellow Head Virus (YHV) / Gill-Associated Virus (GAV)
6.2.1.4. Infectious Myonecrosis Virus (IMNV)
6.2.1.5. White Muscle / White Tail Viral Diseases
6.2.1.6. Others
6.2.2. Bacterial Diseases
6.2.2.1. Vibriosis
6.2.2.2. Acute Hepatopancreatic Necrosis Disease (AHPND/EMS)
6.2.2.3. Vibrio-associated Hepatopancreatic Infections
6.2.3. Bacterial Shell Diseases
6.2.3.1. Chronic Bacterial Septicemia
6.2.3.2. Parasitic & Microsporidian Diseases
6.2.3.3. Enterocytozoon Hepatopenaei (EHP)
6.2.3.4. Gregarine Parasitic Infections
6.2.3.5. Protozoan Fouling Parasites
6.2.3.6. Others
6.2.4. Fungal & Opportunistic Pathogens
Chapter 7. Shrimp Disease Prevention & Therapeutics Market Segmentation 3: By Route of Administration , Estimates & Trend Analysis
7.1. Market Share by Route of Administration , 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Route of Administration :
7.2.1. Oral
7.2.2. Water / Immersion / Bath Application
7.2.3. Injectable Delivery
7.2.4. Topical & External Application
7.2.5. Others
Chapter 8. Shrimp Disease Prevention & Therapeutics Market Segmentation 4: By End-User, Estimates & Trend Analysis
8.1. Market Share by End-User, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following End-User:
8.2.1. Grow-Out Farms
8.2.2. Hatcheries & Nurseries
8.2.3. Integrated Farming & Feed Companies
8.2.4. Diagnostic Laboratories & Research Institute
Chapter 9. Shrimp Disease Prevention & Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Shrimp Disease Prevention & Therapeutics Market, Regional Snapshot 2025 & 2035
9.2. North America
9.2.1. North America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2035
9.2.3. North America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2022-2035
9.2.4. North America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration , 2022-2035
9.2.5. North America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
9.3. Europe
9.3.1. Europe Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2035
9.3.3. Europe Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2022-2035
9.3.4. Europe Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration , 2022-2035
9.3.5. Europe Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
9.4. Asia Pacific
9.4.1. Asia Pacific Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2035
9.4.3. Asia Pacific Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2022-2035
9.4.4. Asia Pacific Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration , 2022-2035
9.4.5. Asia Pacific Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2022-2035
9.5. Latin America
9.5.1. Latin America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2035
9.5.3. Latin America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2022-2035
9.5.4. Latin America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration , 2022-2035
9.5.5. Latin America Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
9.6. Middle East & Africa
9.6.1. Middle East & Africa Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2035
9.6.3. Middle East & Africa Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2022-2035
9.6.4. Middle East & Africa Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration , 2022-2035
9.6.5. Middle East & Africa Shrimp Disease Prevention & Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Zoetis Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Merck Animal Health (Merck & Co., Inc.)
10.2.3. Elanco Animal Health Incorporated
10.2.4. Phibro Animal Health Corporation
10.2.5. Virbac S.A.
10.2.6. Laboratorios HIPRA, S.A. (HIPRA)
10.2.7. Benchmark Holdings plc (INVE Aquaculture & Benchmark Genetics)
10.2.8. Skretting (Nutreco N.V.)
10.2.9. Cargill Aqua Nutrition (Cargill, Incorporated)
10.2.10. Grobest Group
10.2.11. Avanti Feeds Limited
10.2.12. Kemin Industries, Inc. (Kemin AquaScience)
10.2.13. Organica Biotech Private Limited
10.2.14. Sanzyme Biologics Private Limited
10.2.15. ViAqua Therapeutics Ltd.
10.2.16. Syndel Laboratories Ltd.
10.2.17. Kyoto Biken Laboratories, Inc.
10.2.18. Vaxxinova International B.V.
10.2.19. Nisseiken Co., Ltd.
10.2.20. Salem Microbes Private Limited
10.2.21. Others
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Shrimp Disease Prevention and Therapeutics Market is estimated to grow at a 9.4% CAGR during the forecast period for 2026 to 2035.
Zoetis Inc., Merck Animal Health (Merck & Co., Inc.), Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Virbac S.A., Laboratorios HIPRA, S.A. (HIPRA), Benchmark Holdings plc (INVE Aquaculture & Benchmark Genetics), Skretting (Nutreco N.V.), Cargill Aqua Nutrition (Cargill, Incorporated), Grobest Group, Avanti Feeds Limited, Kemin Industries, Inc. (Kemin AquaScience), Organica Biotech Private Limited, Sanzyme Biologics Private Limited , ViAqua Therapeutics Ltd., Syndel Laboratories Ltd., Kyoto Biken Laboratories, Inc. , Vaxxinova International B.V., Nisseiken Co., Ltd. , Salem Microbes Private Limited, Others
Shrimp Disease Prevention and Therapeutics Market segmented by Product Type, Disease Type, Application, End-User, Route of Administration and By Region
Asia Pacific region is leading the Shrimp Disease Prevention and Therapeutics Market.